10-K
Annual Report
10x Genomics, Inc.
TXG
NASDAQ
CIK: 1770787
File #: 001-39035
Balance Sheet
39 line items · 2 periods
XBRL
| Item | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|
Assets | ||
Current assets: | ||
Cash and cash equivalents | 344,067,000 | 359,284,000 |
Marketable securities | 49,335,000 | 29,411,000 |
Accounts receivable, net | 87,862,000 | 114,832,000 |
Inventory | 83,107,000 | 73,706,000 |
Prepaid expenses and other current assets | 20,016,000 | 18,789,000 |
Total current assets | 584,387,000 | 596,022,000 |
Property and equipment, net | 252,648,000 | 279,571,000 |
Operating lease right-of-use assets | 57,290,000 | 65,361,000 |
Goodwill | 4,511,000 | 4,511,000 |
Intangible assets, net | 15,671,000 | 16,616,000 |
Other noncurrent assets | 4,129,000 | 3,062,000 |
Total assets | 918,636,000 | 965,143,000 |
Liabilities and stockholders’ equity | ||
Current liabilities: | ||
Accounts payable | 12,909,000 | 15,738,000 |
Accrued compensation and related benefits | 33,615,000 | 30,105,000 |
Accrued expenses and other current liabilities | 41,165,000 | 56,648,000 |
Deferred revenue | 20,658,000 | 13,150,000 |
2025-01-01 | 20,700,000 | — |
Operating lease liabilities | 9,286,000 | 11,521,000 |
Total current liabilities | 117,633,000 | 127,162,000 |
Operating lease liabilities, noncurrent | 73,327,000 | 83,849,000 |
Deferred revenue, noncurrent | 12,513,000 | 8,814,000 |
Other noncurrent liabilities | 5,029,000 | 4,275,000 |
Total liabilities | 208,502,000 | 224,100,000 |
Stockholders' equity: | ||
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2024 and 2023 | 0 | 0 |
Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 122,291,837 (Class A 108,235,004, Class B 14,056,833) and 119,095,362 (Class A 105,038,529, Class B 14,056,833) shares issued and outstanding as of December 31, 2024 and 2023, respectively | 2,000 | 2,000 |
Additional paid-in capital | 2,177,672,000 | 2,025,890,000 |
Accumulated deficit | (1,467,047,000) | (1,284,420,000) |
Accumulated other comprehensive loss | (493,000) | (429,000) |
Total stockholders’ equity | 710,134,000 | 741,043,000 |
Common Stock | 2,000 | 2,000 |
Additional Paid-in Capital | 2,177,672,000 | 2,025,890,000 |
Accumulated Deficit | (1,467,047,000) | (1,284,420,000) |
Accumulated Other Comprehensive Income (Loss) | (493,000) | (429,000) |
Total liabilities and stockholders’ equity | 918,636,000 | 965,143,000 |